JP6682385B2 - Solid composition - Google Patents
Solid composition Download PDFInfo
- Publication number
- JP6682385B2 JP6682385B2 JP2016130516A JP2016130516A JP6682385B2 JP 6682385 B2 JP6682385 B2 JP 6682385B2 JP 2016130516 A JP2016130516 A JP 2016130516A JP 2016130516 A JP2016130516 A JP 2016130516A JP 6682385 B2 JP6682385 B2 JP 6682385B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- solid composition
- fatty acid
- foam
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Description
本発明は、発泡成分を含有する固形状組成物に関する。 The present invention relates to a solid composition containing a foaming component.
炭酸塩と有機酸の中和反応により炭酸ガスが発生する仕組みを利用した固形状の製品が数多く上市されている。その一つに、発泡錠や発泡顆粒等の経口固形製剤、錠菓等の菓子類がある(例えば、特許文献1、2)。これらは、携帯性や保存性に優れるだけでなく、経口摂取すると口内の唾液や水との接触により発泡し、速やかな崩壊性・溶解性や独特の清涼感が得られることから人気が高まっている。
一方、経口摂取時に口内で発泡させるのではなく、消化管画像診断用の消化管膨張剤のような、経口摂取後に胃等の消化管内で炭酸ガスを発生させる経口固形製剤も知られている。消化管膨張剤は、造影の妨げとならないように、胃の中で発泡した直後に消泡するように作られている。
Many solid products using the mechanism that carbon dioxide is generated by the neutralization reaction of carbonate and organic acid are on the market. One of them is an oral solid preparation such as effervescent tablets and effervescent granules, and confectionery such as tablet confections (for example, Patent Documents 1 and 2). These are not only excellent in portability and storability, but when ingested orally, they foam due to contact with saliva and water in the mouth, and rapid disintegration / solubility and unique cooling sensation are gaining popularity. There is.
On the other hand, oral solid preparations that generate carbon dioxide gas in the digestive tract such as the stomach after oral ingestion, such as a gastrointestinal swelling agent for diagnostic imaging of the digestive tract, are not known to cause foaming in the mouth upon oral intake. The gastrointestinal swelling agent is designed to defoam immediately after foaming in the stomach so as not to interfere with contrast enhancement.
炭酸ガス(気泡)は、一定の時間胃の中に溜まり、胃が膨張すると、脳の満腹中枢が刺激されて、腹部(胃部)膨満感、満腹感をもたらすことが知られている(非特許文献1)。そのため、経口摂取後に、胃の中で生じた泡を消すことなく安定に保持させることができれば、例えば、膨満感や満腹感を与え、食物の摂取量をコントロールする製品等に有用と考えられる。 It is known that carbon dioxide gas (air bubbles) accumulates in the stomach for a certain period of time, and when the stomach expands, it stimulates the satiety center of the brain, resulting in abdominal (stomach) bloating and satiety (non- Patent Document 1). Therefore, if it is possible to stably retain the bubbles generated in the stomach after ingestion without erasing the bubbles, it is considered to be useful for, for example, a product which gives a feeling of fullness or a feeling of fullness and controls food intake.
しかしながら、胃の中で気泡を安定に保つには、唾液がほぼ中性であるのに対して、胃液が強酸性(pH1.0−2.0)であることを考慮する必要がある。また、無理なく継続して経口摂取させるには、それに適した風味が求められる。
したがって、本発明は、胃の中での泡の持続性に優れ、且つ風味の良好な固形状組成物を提供することに関する。
However, in order to keep air bubbles stable in the stomach, it is necessary to consider that the saliva is almost neutral, while the gastric juice is strongly acidic (pH 1.0-2.0). In addition, in order to allow oral ingestion without difficulty, a flavor suitable for it is required.
Therefore, the present invention relates to providing a solid composition having an excellent durability of foam in the stomach and a good taste.
本発明者らは、上記課題を解決するため鋭意検討を重ねた結果、発泡成分に所定の可食性界面活性剤を組み合わせると、胃の中での泡立ちが良く、且つ生じた泡が長時間胃の中で安定に持続することを見出した。また、発泡成分と可食性界面活性剤を組み合わせると、酸味や苦味、エグ味が感じられるようになるが、これらを一定範囲で組み合わせることにより、適度な酸味がありながらも苦味とエグ味が低減されて、風味の良好な固形状組成物とすることができることを見出した。 As a result of intensive studies to solve the above problems, the present inventors have found that when a foaming component is combined with a predetermined edible surfactant, foaming in the stomach is good, and the resulting foam is gastric for a long time. It was found that it lasts stably. When a foaming component and an edible surfactant are combined, you can feel sourness, bitterness, and astringent taste, but by combining these in a certain range, bitterness and astringent taste are reduced while having a moderate sourness. It was found that a solid composition having a good flavor can be obtained.
すなわち、本発明は、次の成分(A)、(B)及び(C):
(A)HLBが12以上の可食性界面活性剤 3〜60質量%、
(B)炭酸塩 5〜27質量%、
(C)有機酸 5〜27質量%
を含有し、成分(C)/成分(B)の中和度が1.25〜7であり、且つ成分(A)の含有量に対する成分(B)と成分(C)の合計含有量の比(含有質量比)[{(B)+(C)}/(A)]が0.6〜10である固形状組成物を提供するものである。
That is, the present invention provides the following components (A), (B) and (C):
(A) Edible surfactant having HLB of 12 or more 3 to 60% by mass,
(B) Carbonate 5 to 27% by mass,
(C) Organic acid 5 to 27 mass%
And the neutralization degree of component (C) / component (B) is 1.25 to 7, and the ratio of the total content of component (B) and component (C) to the content of component (A). A solid composition having a (content mass ratio) [{(B) + (C)} / (A)] of 0.6 to 10 is provided.
本発明によれば、胃の中での泡立ち及び泡の持続性に優れ、且つ適度な酸味がありながらも苦味とえぐ味が少ない、風味の良好な固形状組成物を提供することができる。 According to the present invention, it is possible to provide a solid composition which is excellent in foaming in the stomach and the durability of foam, and which has a suitable sourness but little bitterness and dull taste and has a good flavor.
本発明において、「可食性界面活性剤」とは、食品用および医薬品用に一般的に用いられる界面活性剤を示す。本発明で用いられる成分(A)の可食性界面活性剤は、そのHLBが12以上である。固形状組成物中に、所定のHLBを有する可食性界面活性剤を後述の発泡成分と共に含有させることで、胃の中で発泡成分の反応を促し、且つ生じた泡を安定して保持することができる。
ここで、HLB(親水性−親油性のバランス、Hydrophilic−Lypophilic Balance)は、界面活性剤の全分子量に占める親水基部分の分子量を示すものである。可食性界面活性剤のHLBは、グリフィン(Griffin)の式により求められる。なお、2種以上の可食性界面活性剤から構成される場合のHLBは、各可食性界面活性剤のHLB値をその配合質量比率に基づいて相加算平均する。
In the present invention, the “edible surfactant” refers to a surfactant that is generally used for foods and pharmaceuticals. The edible surfactant as the component (A) used in the present invention has an HLB of 12 or more. By containing an edible surfactant having a predetermined HLB in the solid composition together with the foaming component described below, the reaction of the foaming component in the stomach is promoted and the generated foam is stably retained. You can
Here, HLB (hydrophilic-lipophilic balance, Hydrophilic-Lypophilic Balance) indicates the molecular weight of the hydrophilic group portion in the total molecular weight of the surfactant. The HLB of the edible surfactant is calculated by the Griffin equation. When the HLB is composed of two or more kinds of edible surfactants, the HLB value of each edible surfactant is subjected to a phase addition average based on the blending mass ratio.
(A)可食性界面活性剤のHLBは、12以上であるが、胃の中での泡の持続性が良好である点から14以上であるのが好ましく、また、HLBが17以下であるのが好ましく、16以下であるのがより好ましい。 (A) The edible surfactant has an HLB of 12 or more, but is preferably 14 or more from the viewpoint of good sustainability of foam in the stomach, and has an HLB of 17 or less. Is preferable, and 16 or less is more preferable.
(A)HLBが12以上の可食性界面活性剤としては、例えば、ショ糖脂肪酸エステル、ポリグリセリン脂肪酸エステル等が挙げられる。 Examples of the edible surfactant (A) having an HLB of 12 or more include sucrose fatty acid ester and polyglycerin fatty acid ester.
ショ糖脂肪酸エステルは、ショ糖の水酸基に脂肪酸がエステル結合してなる界面活性剤で、モノエステルの他、ジエステル、トリエステル、ポリエステルが含有されていてもよい。
なかでも、風味の点から、ショ糖脂肪酸エステルのモノエステルの含有量は60質量%(以下、単位「%」とする)以上、更に65%以上であるのが好ましい。
The sucrose fatty acid ester is a surfactant in which a fatty acid is ester-bonded to the hydroxyl group of sucrose, and may contain a diester, a triester, or a polyester in addition to the monoester.
Among them, the content of the monoester of sucrose fatty acid ester is preferably 60% by mass (hereinafter, referred to as a unit "%") or more, and more preferably 65% or more from the viewpoint of flavor.
ショ糖脂肪酸エステルを構成する脂肪酸は、固形状組成物に使用可能な点から、炭素数12〜22の飽和又は不飽和脂肪酸であるのが好ましく、更に炭素数12〜18の飽和又は不飽和脂肪酸、更に炭素数16〜18の飽和又は不飽和脂肪酸であるのが好ましい。なかでも、炭素数18の飽和又は不飽和脂肪酸は、総脂肪酸量の60%以上であるのが好ましい。炭素数18の飽和又は不飽和脂肪酸としては、ステアリン酸、オレイン酸が好ましく、ステアリン酸がより好ましい。 The fatty acid that constitutes the sucrose fatty acid ester is preferably a saturated or unsaturated fatty acid having 12 to 22 carbon atoms, and more preferably a saturated or unsaturated fatty acid having 12 to 18 carbon atoms, from the viewpoint that it can be used in a solid composition. Furthermore, it is preferably a saturated or unsaturated fatty acid having 16 to 18 carbon atoms. Among them, the saturated or unsaturated fatty acid having 18 carbon atoms preferably accounts for 60% or more of the total fatty acid content. As the saturated or unsaturated fatty acid having 18 carbon atoms, stearic acid and oleic acid are preferable, and stearic acid is more preferable.
ポリグリセリン脂肪酸エステルは、ポリグリセリンと脂肪酸とのエステルである。このポリグリセリンにおけるグリセリンの平均重合度は、一般的に広く用いられている点、泡の持続性が良好である点から、7以上が好ましく、10であるのがより好ましい。ここで、グリセリンの平均重合度は、末端基分析法により求めた値をいう。末端基分析法とは、以下の方法である。水酸基価(OHV)の測定値と理論値の関係から、次式により重合度nと分子量(MW)を求める。
MW=74n+18
OHV=56110(n+2)/MW
水酸基価の測定法としては、無水酢酸・ピリジン法または無水フタル酸・ピリジン法がある。
Polyglycerin fatty acid ester is an ester of polyglycerin and fatty acid. The average degree of polymerization of glycerin in this polyglycerin is preferably 7 or more, and more preferably 10 from the viewpoint that it is widely used and that the foam lasts well. Here, the average degree of polymerization of glycerin refers to a value obtained by an end group analysis method. The terminal group analysis method is the following method. From the relationship between the measured hydroxyl value (OHV) and the theoretical value, the degree of polymerization n and the molecular weight (MW) are calculated by the following equations.
MW = 74n + 18
OHV = 56110 (n + 2) / MW
The hydroxyl value can be measured by acetic anhydride / pyridine method or phthalic anhydride / pyridine method.
ポリグリセリン脂肪酸エステルを構成する脂肪酸は、固形状組成物に利用する点から、炭素数12〜22の飽和又は不飽和脂肪酸であるのが好ましく、更に炭素数12〜18の飽和又は不飽和脂肪酸、更に炭素数16〜18の飽和又は不飽和脂肪酸であるのが好ましい。なかでも、炭素数18の飽和脂肪酸は、総脂肪酸量の60%以上であるのが好ましい。 The fatty acid constituting the polyglycerin fatty acid ester is preferably a saturated or unsaturated fatty acid having 12 to 22 carbon atoms, and further a saturated or unsaturated fatty acid having 12 to 18 carbon atoms, from the viewpoint of use in a solid composition. Further, it is preferably a saturated or unsaturated fatty acid having 16 to 18 carbon atoms. Among them, the saturated fatty acid having 18 carbon atoms is preferably 60% or more of the total fatty acid content.
(A)HLBが12以上の可食性界面活性剤は、既知の合成法を利用して調製しても、また、市販品を用いてもよく、また、必要に応じて市販品を分画し、再構成することによって調製してもよい。 (A) The edible surfactant having an HLB of 12 or more may be prepared by a known synthesis method, or a commercially available product may be used. If necessary, the commercially available product may be fractionated. , May be prepared by reconstitution.
(A)HLBが12以上の可食性界面活性剤は、1種又は2種以上を組み合わせて用いることができる。
本発明の固形状組成物中、(A)HLBが12以上の可食性界面活性剤の含有量は3〜60%であるが、胃の中での泡の持続性が良好である点から、5〜60%、更に5〜45%、更に10〜45%、更に10〜30%であるのが好ましい。
The edible surfactant (A) having an HLB of 12 or more can be used alone or in combination of two or more.
In the solid composition of the present invention, the content of the edible surfactant (A) HLB of 12 or more is 3 to 60%, but from the point that the sustainability of foam in the stomach is good, It is preferably 5 to 60%, further 5 to 45%, further 10 to 45%, further 10 to 30%.
本発明の固形状組成物は、発泡成分として(B)炭酸塩と(C)有機酸を含有する。
本発明で用いられる(B)炭酸塩としては、例えば、炭酸ナトリウム、炭酸水素ナトリウム、炭酸カリウム、炭酸水素カリウム、炭酸カルシウム、炭酸マグネシウム、セスキ炭酸ナトリウム等が挙げられる。なかでも、泡の持続性が良好である点、食感が良好である点から、炭酸ナトリウム、炭酸水素ナトリウムが好ましく、炭酸水素ナトリウムが更に好ましい。
The solid composition of the present invention contains (B) carbonate and (C) organic acid as foaming components.
Examples of the (B) carbonate used in the present invention include sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, calcium carbonate, magnesium carbonate, sodium sesquicarbonate and the like. Of these, sodium carbonate and sodium hydrogen carbonate are preferable, and sodium hydrogen carbonate is more preferable, from the viewpoints of good foam persistence and good texture.
(B)炭酸塩は、単独で又は2種以上を組み合わせて用いることができる。
本発明の固形状組成物中、(B)炭酸塩の含有量は、5〜27%であるが、生じる泡の量が多い点、苦味、エグ味を少なくするという点から、10〜25%、更に10〜20%であるのが好ましい。
The carbonate (B) can be used alone or in combination of two or more kinds.
In the solid composition of the present invention, the content of the (B) carbonate is 5 to 27%, but 10 to 25% from the viewpoint that a large amount of foam is generated, bitterness and astringency are reduced. And more preferably 10 to 20%.
本発明で用いられる(C)有機酸としては、可食性の酸を使用することができる。例えば、クエン酸、コハク酸、アスコルビン酸、酢酸、グルコン酸、リンゴ酸、酒石酸、フマル酸、アジピン酸等の有機酸が挙げられる。なかでも、口腔中で雑味を感じず適度な酸味がたつ点から、クエン酸又はリンゴ酸が好ましく、更にクエン酸が好ましい。 As the organic acid (C) used in the present invention, an edible acid can be used. Examples thereof include organic acids such as citric acid, succinic acid, ascorbic acid, acetic acid, gluconic acid, malic acid, tartaric acid, fumaric acid and adipic acid. Among them, citric acid or malic acid is preferable, and citric acid is more preferable, from the viewpoint that it does not feel an unpleasant taste in the oral cavity and has an appropriate sourness.
(C)有機酸は、単独で又は2種以上を組み合わせて用いることができる。
本発明の固形状組成物中、(C)有機酸の含有量は、5〜27%であるが、生じる泡の量が多い点、適度な酸味が感じられる点から、更に10〜27%、更に10〜25%であるのが好ましい。
The (C) organic acid may be used alone or in combination of two or more kinds.
In the solid composition of the present invention, the content of the organic acid (C) is 5 to 27%, but from the point that a large amount of foam is generated and a suitable sourness is felt, further 10 to 27%, Further, it is preferably 10 to 25%.
また、本発明の固形状組成物中、(B)炭酸塩と(C)有機酸の合計含有量は、生じる泡の量が多い点、苦味、エグ味を少なくするという点から、10〜54%、更に20〜50%、更に30〜50%が好ましい。 Further, in the solid composition of the present invention, the total content of (B) carbonate and (C) organic acid is from 10 to 54 from the viewpoint that a large amount of bubbles are generated, bitterness and astringency are reduced. %, More preferably 20 to 50%, further preferably 30 to 50%.
本発明において、成分(C)/成分(B)の中和度は、1.25〜7である。
ここで、成分(C)/成分(B)の中和度とは、固形状組成物に含まれる(C)有機酸の当量を(B)炭酸塩の当量で除した値であり、次式により求めることができる。
中和度={成分(C)の質量%/成分(B)の質量%}/{成分(C)1g当量/成分(B)1g当量}
成分(C)/成分(B)の中和度は、味の点から、1.25〜4であるのが好ましく、更に1.25〜3であるのが好ましく、更に1.25〜2であるのが好ましい。
In the present invention, the degree of neutralization of component (C) / component (B) is 1.25 to 7.
Here, the degree of neutralization of component (C) / component (B) is a value obtained by dividing the equivalent amount of (C) organic acid contained in the solid composition by the equivalent amount of (B) carbonate. Can be obtained by
Degree of neutralization = {mass% of component (C) / mass% of component (B)} / {component (C) 1 g equivalent / component (B) 1 g equivalent}
From the viewpoint of taste, the degree of neutralization of the component (C) / component (B) is preferably 1.25 to 4, more preferably 1.25 to 3, and further 1.25 to 2. Preferably.
本発明において、固形状組成物中の(A)HLBが12以上の可食性界面活性剤の含有量に対する、固形状組成物中の(B)炭酸塩と(C)有機酸の合計含有量の比(含有質量比)[{(B)+(C)}/(A)]は、0.6〜10であるが、胃の中での泡の持続性が良好である点、苦味、エグ味を少なくするという点から、更に0.66〜6、更に3〜6であるのが好ましい。 In the present invention, the total content of (B) carbonate and (C) organic acid in the solid composition is based on the content of the edible surfactant having (A) HLB of 12 or more in the solid composition. The ratio (content ratio by mass) [{(B) + (C)} / (A)] is 0.6 to 10, but the point that the sustainability of bubbles in the stomach is good, bitterness, and ag From the viewpoint of reducing the taste, it is more preferably 0.66 to 6, and further preferably 3 to 6.
本発明の固形状組成物には、上記成分の他に、本発明の効果を損なわない範囲において、ミネラル(例えば、カルシウム、マグネシウム、鉄、亜鉛、クロム、セレン、マンガン、モリブデン、銅、ヨウ素、リン、カリウム、ナトリウム)、ビタミン(例えば、ビタミンA、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12、ビタミンC、ビタミンE、葉酸及びそれらの塩、又はそれらのエステル)、甘味料(例えば、フルクトース、グルコース、ガラクトース、キシロース等の単糖;ショ糖、乳糖、麦芽糖、トレハロース、イソマルトオリゴ糖、ガラクトオリゴ糖、フラクトオリゴ糖、乳果オリゴ糖、大豆オリゴ糖、イソマルツロース、カップリングシュガー等の少糖;糖アルコール、サッカリン、スクラロース、ステビア、アセスルファムカリウム等の合成甘味料)、(A)以外の界面活性剤、(C)有機酸以外の酸味料、香料、着色料、保存料等が適宜配合されていてもよい。 In the solid composition of the present invention, in addition to the above components, in a range that does not impair the effects of the present invention, minerals (for example, calcium, magnesium, iron, zinc, chromium, selenium, manganese, molybdenum, copper, iodine, Phosphorus, potassium, sodium), vitamins (eg vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin E, folic acid and salts thereof, or esters thereof), sweeteners (eg fructose) , Monosaccharides such as glucose, galactose, xylose; sucrose, lactose, maltose, trehalose, isomaltooligosaccharides, galactooligosaccharides, fructooligosaccharides, lactose oligosaccharides, soybean oligosaccharides, isomaltulose, coupling sugars and other oligosaccharides ; Sugar alcohol, saccharin, sucralose, stevia, a Sul Pham synthetic sweeteners such as potassium), surfactants other than (A), (C) other than the organic acid acidulant, flavoring, coloring, preservatives, etc. may be appropriately blended.
本発明の固形状組成物は、口内の唾液又は水の存在下で炭酸ガスを発生するものである。とりわけ、経口摂取後、胃内の水分と反応して発泡し、且つ生じた泡が長時間胃の中で安定に持続する。そのため、本発明の固形状組成物は、腹部(胃部)膨満感、満腹感を与え、食物の摂取量をコントロールする製品等として好適である。尚、胃液のpHは、状況によりその酸性度は変化するものの、一般的にpH1.0〜2.0である。
本発明の固形状組成物は、後述する実施例に記載の胃液モデルを用いた泡安定性の評価による相対泡量(%)が45%以上であることが好ましく、更に50%以上、更に70%以上であることが好ましい。この値が大きいほうが、胃の中での泡の持続性に優れると判断できる。
The solid composition of the present invention generates carbon dioxide gas in the presence of saliva or water in the mouth. In particular, after ingestion, it reacts with water in the stomach to foam, and the resulting foam is stable in the stomach for a long time. Therefore, the solid composition of the present invention is suitable as a product or the like which gives a feeling of fullness and a feeling of fullness in the abdomen (stomach) and controls the intake of food. The pH of gastric juice is generally 1.0 to 2.0, although its acidity changes depending on the situation.
The solid composition of the present invention preferably has a relative foam amount (%) of 45% or more, further 50% or more, further 70 by the foam stability evaluation using a gastric juice model described in Examples described later. % Or more is preferable. It can be judged that the larger this value is, the more excellent the durability of the foam in the stomach is.
本発明の固形状組成物は、室温(15〜25℃)で固形状態のものを意味し、粉末、固形、顆粒等の形態が挙げられる。更に、具体的な製剤(剤型)としては、例えば、カプセル剤、顆粒剤、散剤、錠剤、丸剤、トローチ剤等が挙げられる。なかでも、摂取が簡便な点、食品として摂取する点から、発泡錠である錠剤、顆粒剤、散剤、丸剤、トローチ剤が好ましく、口腔内での滞留時間の短さから、錠剤、顆粒剤、散剤が更に好ましい。錠剤の形状としては、円形錠又は楕円形、長円形、四角形等の面形を有する各種異形錠であってもよい。円形錠の場合、服用性の点から、直径5〜15mmが好ましい。また、錠剤の重量は、一製剤当たり0.1〜2g、更に0.3〜1gとするのが、簡便性及び有効性の点で好ましい。 The solid composition of the present invention means a solid composition at room temperature (15 to 25 ° C.), and examples thereof include powder, solid, and granule forms. Further, specific formulations (dosage forms) include, for example, capsules, granules, powders, tablets, pills, troches, and the like. Among them, effervescent tablets, granules, powders, pills, and lozenges are preferable from the viewpoints of easy intake and food, and tablets and granules are preferred because of their short residence time in the oral cavity. Further, a powder is more preferable. The shape of the tablet may be a circular tablet or various irregularly shaped tablets having an oval shape, an oval shape, a square shape or the like. In the case of a circular tablet, a diameter of 5 to 15 mm is preferable from the viewpoint of ingestability. Further, the weight of the tablet is preferably 0.1 to 2 g, more preferably 0.3 to 1 g, per preparation, in terms of simplicity and effectiveness.
固形状の組成物を調製するには、必要に応じて許容される担体を配合することができる。例えば、賦形剤(例えば、デンプン類、結晶セルロース、軽質無水ケイ酸、リン酸水素カルシウム等)、結合剤(例えば、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、ゼラチン、アルファー化デンプン、ポリビニルピロリドン、ポリビニルアルコール、プルラン、メチルセルロース、硬化油等)、崩壊剤(例えば、カルメロース、カルメロースカルシウム、クロスカルメロースナトリウム、クロスポピドン、トウモロコシデンプン、低置換度ヒドロキシプロピルセルロース等)、滑沢剤(例えば、ステアリン酸カルシウム、ステアリン酸マグネシウム、フマル酸ステアリルナトリウム、タルク、二酸化ケイ素等)、増量剤、分散剤、緩衝剤、希釈剤等の担体が挙げられる。 In order to prepare a solid composition, an acceptable carrier can be blended if necessary. For example, excipients (eg starches, crystalline cellulose, light anhydrous silicic acid, calcium hydrogen phosphate, etc.), binders (eg hydroxypropylmethyl cellulose, hydroxypropyl cellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol) , Pullulan, methylcellulose, hydrogenated oil, etc.), disintegrant (eg, carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, low-substituted hydroxypropylcellulose, etc.), lubricant (eg, calcium stearate, Carriers such as magnesium stearate, sodium stearyl fumarate, talc, silicon dioxide), extenders, dispersants, buffers, diluents and the like can be mentioned.
本発明の固形状組成物は、特に制限はなく常法に従い製造される。
例えば、散剤を製造する場合、(A)HLBが12以上の可食性界面活性剤、(B)炭酸塩、(C)有機酸及び必要に応じて添加される添加剤を混合し、その混合物をそのまま用いてもよいし、混合物を粉砕して用いてもよい。散剤は、18号(850μm)ふるいを全量通過することが好ましく、300号(500μm)ふるいに残留するものが全量の5%以下であることがより好ましい。
The solid composition of the present invention is not particularly limited and can be produced according to a conventional method.
For example, in the case of producing a powder, (A) an edible surfactant having an HLB of 12 or more, (B) a carbonate, (C) an organic acid, and an additive which is added as necessary are mixed, and the mixture is mixed. The mixture may be used as it is, or the mixture may be crushed before use. The powder preferably passes through the No. 18 (850 μm) sieve in the entire amount, and more preferably remains in the No. 300 (500 μm) sieve at 5% or less of the total amount.
顆粒剤は、(A)HLBが12以上の可食性界面活性剤、(B)炭酸塩、(C)有機酸及び必要に応じて添加される添加剤を混合し、その混合物を乾式造粒法、湿式造粒法等を用いて造粒することにより得ることができる。造粒法としては、押し出し造粒法、破砕造粒法、転動造粒法、攪拌造粒法、流動層造粒法等が挙げられる。造粒物の平均粒子径は、45μm〜850μmとするのが好ましく、100μm〜500μmとするのが更に好ましい。 The granules are prepared by mixing (A) an edible surfactant having an HLB of 12 or more, (B) a carbonate, (C) an organic acid, and an additive added as necessary, and subjecting the mixture to a dry granulation method. It can be obtained by granulating using a wet granulation method or the like. Examples of the granulation method include an extrusion granulation method, a crushing granulation method, a tumbling granulation method, a stirring granulation method, and a fluidized bed granulation method. The average particle size of the granulated product is preferably 45 μm to 850 μm, and more preferably 100 μm to 500 μm.
錠剤を製造する場合は、(A)HLBが12以上の可食性界面活性剤、(B)炭酸塩、(C)有機酸及び必要に応じて添加される添加剤を混合し、その混合物を原料粉末として直接圧縮して成形しても、前記乾式造粒法、湿式造粒法等を用いて造粒してから、造粒物を打錠成形機で圧縮して成形しても良い。
直接又は造粒物を圧縮して成形して錠剤を製造する場合、打錠成形機としてはロータリー式打錠機や単発式打錠機等通常使用されるものを用いることができる。
打錠時の圧縮成型圧は、成型物の硬度維持の点から、10〜30MPa程度が好ましい。
また、錠剤硬度は、運搬や保存等に耐え得る硬度であることが好ましく、また、胃の中での泡の持続性を考慮して、10N〜200N程度が好ましい。
In the case of producing a tablet, (A) an edible surfactant having an HLB of 12 or more, (B) a carbonate, (C) an organic acid, and an additive added as necessary are mixed, and the mixture is used as a raw material. The powder may be directly compressed and molded, or may be granulated using the dry granulation method, the wet granulation method or the like, and then the granulated product may be compressed by a tablet molding machine to be molded.
When a tablet is produced directly or by compressing a granulated product to form a tablet, a tableting machine such as a rotary tableting machine or a single-shot tableting machine can be used.
The compression molding pressure during tableting is preferably about 10 to 30 MPa from the viewpoint of maintaining the hardness of the molded product.
Further, the tablet hardness is preferably a hardness that can withstand transportation, storage, and the like, and is preferably about 10 N to 200 N in consideration of the sustainability of bubbles in the stomach.
[炭酸塩の分析]
固形状組成物中の炭酸塩の含有量の分析方法は以下の通りである。
固形状組成物を0.1〜0.2g採取し、水10mLと50%りん酸2mLを加え密栓した。10分間超音波処理を行った後、1時間放置しヘッドスペースガスをガスクロマトグラフに供してCO2量を求め、発生したCO2量から算出した。
<ガスクロマトグラフ操作条件>
機種:GC−14B[島津製作所]
検出器:TCD
カラム:Chromosorb101,80〜100mesh
ガラス管,φ3.2mm×2m
温度:カラム50℃,注入口及び検出器100℃
セル電流75mA
ガス圧力:ヘリウム(キャリヤーガス)100kPa
注入量:ヘッドスペースガス0.2mL
[Carbonate analysis]
The analysis method of the content of carbonate in the solid composition is as follows.
0.1 to 0.2 g of the solid composition was collected, 10 mL of water and 2 mL of 50% phosphoric acid were added, and the container was sealed. After sonication for 10 minutes, one hour left headspace gas determine the amount of CO 2 was subjected to gas chromatography, was calculated from the generated amount of CO 2.
<Operating conditions for gas chromatograph>
Model: GC-14B [Shimadzu]
Detector: TCD
Column: Chromsorb 101, 80-100 mesh
Glass tube, φ3.2mm × 2m
Temperature: Column 50 ° C, inlet and detector 100 ° C
Cell current 75mA
Gas pressure: Helium (carrier gas) 100 kPa
Injection volume: Headspace gas 0.2mL
[有機酸の分析]
固形状組成物中の有機酸の含有量の分析方法は以下の通りである。
固形状組成物を1g採取し5%過塩素酸20mLを加え、10分間振とうすることで抽出した。これを水で200mLに定容し10分間超音波処理を行った。ろ過後高速液体クロマトグラフに供した。
<高速液体クロマトグラフ操作条件>
機種:LC−20AD[株式会社島津製作所]
検出器:紫外可視吸光光度計SPD−20AV[島津製作所]
カラム:Shim−pack SCR−102H 300×80(長さ×内径(mm))
[島津製作所]
カラム温度:40℃
移動相:3mmоl/L過塩素酸
反応液:0.2mmоl/Lブロムチモールブルー含有
15mmоl/Lりん酸水素二ナトリウム溶液
流量:移動相1.0mL/min、反応液1.4mL/min
測定波長:445nm
[Analysis of organic acids]
The method for analyzing the content of the organic acid in the solid composition is as follows.
1 g of the solid composition was sampled, 20 mL of 5% perchloric acid was added, and the mixture was shaken for 10 minutes for extraction. This was adjusted to 200 mL with water and sonicated for 10 minutes. After filtration, it was subjected to high performance liquid chromatography.
<Operating conditions for high-performance liquid chromatography>
Model: LC-20AD [Shimadzu Corporation]
Detector: UV-visible absorption spectrophotometer SPD-20AV [Shimadzu]
Column: Shim-pack SCR-102H 300 x 80 (length x inner diameter (mm))
[Shimadzu]
Column temperature: 40 ° C
Mobile phase: 3 mm / l perchloric acid reaction solution: 0.2 mm / l containing bromthymol blue 15 mm / l disodium hydrogen phosphate solution flow rate: mobile phase 1.0 mL / min, reaction solution 1.4 mL / min
Measurement wavelength: 445 nm
[原料]
可食性界面活性剤として、表1に示すSA−1〜SA−19を用いた。
[material]
SA-1 to SA-19 shown in Table 1 were used as the edible surfactant.
また、次の原料を用いた。
炭酸水素ナトリウム:重曹(食添C)、東ソー
クエン酸:無水クエン酸MS、扶桑化学工業(株)
リンゴ酸:フソウS、扶桑化学工業(株)
コハク酸:コハク酸、日本触媒(株)
ステアリン酸カルシウム:オーラブライトCA−65、日油(株)
マルチトール:アマルティMR−50、三菱商事フードテック(株)
The following raw materials were used.
Sodium hydrogen carbonate: baking soda (Food additive C), Tosoh citric acid: anhydrous citric acid MS, Fuso Chemical Industry Co., Ltd.
Malic acid: Fuso S, Fuso Chemical Industry Co., Ltd.
Succinic acid: succinic acid, Nippon Shokubai Co., Ltd.
Calcium stearate: Aura Bright CA-65, NOF Corporation
Maltitol: Amarti MR-50, Mitsubishi Corporation Foodtech Co., Ltd.
試験例1〜19
〔固形状組成物の調製〕
表2に記載の配合組成で各原料成分を均一に混合し、粉末状の組成物を得た。可食性界面活性剤(SA−1〜SA−19)のカッコ内の数値はHLBを示す。各組成物における成分(C)/成分(B)の中和度、可食性界面活性剤(SA−1〜SA−19)の含有量に対する成分(B)と成分(C)の合計含有量の比(含有質量比)は表2のとおりであった。
Test Examples 1 to 19
[Preparation of solid composition]
Each raw material component was uniformly mixed in the composition shown in Table 2 to obtain a powdery composition. The numerical value in the parentheses of the edible surfactants (SA-1 to SA-19) indicates HLB. Degree of neutralization of component (C) / component (B) in each composition, of the total content of component (B) and component (C) with respect to the content of edible surfactants (SA-1 to SA-19) The ratio (content mass ratio) was as shown in Table 2.
〔泡安定性の評価〕
上記で得た本発明品と比較品について泡安定性を次のとおり評価した。
(1)1g当たりの理論泡量の定義と算出
固形状組成物中の炭酸塩と有機酸の反応により生成する二酸化炭素のモル数は、炭酸塩の質量を炭酸塩の1グラム当量で除した値と、有機酸の質量を有機酸の1グラム当量で除した値のうち最も小さな値(Mi)となる。一方、1モルの理想気体の体積は、標準状態(0℃、1bar)下で22.7リットルである。そこで、本明細書においては、前記Miに22.7リットルを乗じた値を、固形状組成物1g当たりの理論泡量(mL)とした。
[Evaluation of foam stability]
The foam stability of the product of the present invention and the comparative product obtained above were evaluated as follows.
(1) Definition and calculation of theoretical foam amount per 1 g The number of moles of carbon dioxide produced by the reaction of the carbonate and the organic acid in the solid composition is obtained by dividing the mass of carbonate by 1 gram equivalent of carbonate. It becomes the smallest value (Mi) of the value and the value obtained by dividing the mass of the organic acid by 1 gram equivalent of the organic acid. On the other hand, the volume of 1 mol of ideal gas is 22.7 liters under standard conditions (0 ° C., 1 bar). Therefore, in the present specification, a value obtained by multiplying Mi by 22.7 liters is defined as a theoretical foam amount (mL) per 1 g of the solid composition.
(2)胃液モデル液
胃液モデル液として、第16版改正日本薬局方に準拠した崩壊試験第1液(pH1.2)を用いた。
(2) Gastric fluid model fluid As the gastric fluid model fluid, the disintegration test first fluid (pH 1.2) according to the 16th edition revised Japanese Pharmacopoeia was used.
(3)相対泡量の定義と算出
上記胃液モデル液に投じた固形状組成物1gから生じる実際の泡量(実測量)(mL)を固形状組成物1g当たりの理論泡量(mL)で除し、百分率で示した値を相対泡量(%)とした。
相対泡量(%)=〔実測量(mL)〕/〔1g当たりの理論泡量(mL)〕×100
実測量(mL)は、50mLメスシリンダーにサンプル1gを入れ、上記胃液モデル液を2mL添加し、添加直後を0分とし、15分後の泡上部の目盛りを読み取った。
本発明品と比較品それぞれの理論泡量(mL)、実測量(mL)及び相対泡量(%)を表2に示す。
(3) Definition and calculation of relative foam amount The actual foam amount (measured amount) (mL) generated from 1 g of the solid composition thrown into the gastric juice model liquid is expressed as the theoretical foam amount (mL) per 1 g of the solid composition. The relative foam amount (%) was determined by dividing the value by percentage.
Relative foam amount (%) = [measured amount (mL)] / [theoretical foam amount per 1 g (mL)] × 100
As for the actually measured amount (mL), 1 g of the sample was put into a 50 mL graduated cylinder, 2 mL of the above gastric juice model solution was added, and 0 minutes was set immediately after the addition, and the scale above the foam was read 15 minutes later.
Table 2 shows the theoretical bubble amount (mL), the measured amount (mL), and the relative bubble amount (%) of the product of the present invention and the comparative product.
表2より明らかなように、HLBが12以上の可食性界面活性剤を配合した本発明品は、比較品と比べて実測量(mL)及び相対泡量(%)が高く、胃の中で発泡し、且つ生じた泡が消えることなく長時間安定に持続することが確認された。 As is clear from Table 2, the product of the present invention containing an edible surfactant having an HLB of 12 or more has a higher actual measured amount (mL) and relative foam amount (%) than the comparative product, and therefore, in the stomach. It was confirmed that foaming occurred and that the generated foam remained stable for a long time without disappearing.
試験例20〜48
〔固形状組成物の調製〕
表3又は表4に記載の配合組成で各原料成分を混合し、粉末状の組成物を得た。各組成物における成分(C)/成分(B)の中和度、成分(A)の含有量に対する成分(B)と成分(C)の合計含有量の比(含有質量比)は表3又は表4のとおりであった。
Test Examples 20 to 48
[Preparation of solid composition]
Each raw material component was mixed with the composition shown in Table 3 or Table 4 to obtain a powdery composition. The degree of neutralization of component (C) / component (B) in each composition and the ratio of the total content of component (B) and component (C) to the content of component (A) (content mass ratio) are shown in Table 3 or The results are shown in Table 4.
〔泡安定性の評価〕
上記で得た本発明品と比較品について泡安定性を同様に評価した。それぞれの理論泡量(mL)、実測量(mL)及び相対泡量(%)を表3及び表4に示す。
[Evaluation of foam stability]
The foam stability of the inventive product and the comparative product obtained above were evaluated in the same manner. Tables 3 and 4 show the theoretical foam volume (mL), the measured volume (mL) and the relative foam volume (%), respectively.
〔官能評価〕
また、本発明品と比較品について3名の専門パネルによる官能評価を行なった。評価は、サンプルを食べた時に感じる酸味、苦味とエグ味の強度について、下記に示す判断基準に従って行い、協議により評点を決定した。結果を表3及び表4に示す。
(酸味の強度)
5:酸味が弱い
4:酸味がやや弱い
3:酸味がちょうど良い
2:酸味がやや強い
1:酸味が強い
(苦味とエグ味の強度)
4:苦味とエグ味が弱い
3:苦味とエグ味がやや弱い
2:苦味とエグ味がやや強い
1:苦味とエグ味が強い
〔sensory evaluation〕
Further, the invented product and the comparative product were subjected to a sensory evaluation by three expert panels. The evaluation was carried out according to the criteria shown below for the sourness, bitterness and astringency felt when the sample was eaten, and the scores were determined through discussion. The results are shown in Tables 3 and 4.
(Sourness intensity)
5: Weak sourness 4: Slightly sourness 3: Just sourness 2: Slightly sourness 1: Strong sourness (bitterness and astringency)
4: Bitterness and astringency are weak 3: Bitterness and astringency are a little weak 2: Bitterness and astringency are a little strong 1: Bitterness and astringency are strong
表3及び表4から明らかなように、本発明品は、相対泡量(%)が高く、胃の中で発泡し、且つ生じた泡が消えることなく長時間安定に持続することが確認された。また、本発明品は、適度な酸味を有しつつも、苦味とエグ味の少ない良好な風味であった。
これに対して、HLBが12以上の可食性界面活性剤を所定範囲で配合しなかった比較品は、実測量(mL)及び相対泡量(%)が低く、胃の中ですぐに泡が消えてしまった。また、酸味の強度が好ましくなかったり、苦味とエグ味が感じられたりする場合があった。
As is clear from Tables 3 and 4, it was confirmed that the product of the present invention has a high relative foam amount (%), foams in the stomach, and the foam generated does not disappear and remains stable for a long time. It was In addition, the product of the present invention had a good sourness with little bitterness and astringent taste while having an appropriate sourness.
On the other hand, the comparative product in which the edible surfactant having HLB of 12 or more was not mixed in the predetermined range had a low actual measurement amount (mL) and a relative foam amount (%), and the foam immediately formed in the stomach. It has disappeared. In addition, the strength of sourness was not preferable, and bitterness and astringency were sometimes felt.
試験例49〜55
〔固形状組成物の調製〕
表5に記載の配合組成で各原料成分を均一に混合し、次いで単発式打錠機(RIKEN製)を用いて、穴径14mmのリング状杵で錠剤重量1000mg/1錠で打錠し、円形の錠剤を得た。試験例49と50、試験例51と52、試験例53と54は、それぞれ打錠圧を調整して錠剤の硬度を変化させた。錠剤硬度は、Hardness Tester(藤原製作所製)を用いて直径方向の硬度を測定した。
各錠剤における成分(C)/成分(B)の中和度、成分(A)の含有量に対する成分(B)と成分(C)の合計含有量の比(含有質量比)、錠剤の硬度、厚さ及び直径を表5に示した。
Test Examples 49 to 55
[Preparation of solid composition]
Each raw material component was uniformly mixed with the composition shown in Table 5, and then tableted with a ring punch having a hole diameter of 14 mm at a tablet weight of 1000 mg / 1 tablet using a single-shot tableting machine (manufactured by RIKEN). Round tablets were obtained. In Test Examples 49 and 50, Test Examples 51 and 52, and Test Examples 53 and 54, the tableting pressure was adjusted to change the hardness of the tablets. For the tablet hardness, the hardness in the diameter direction was measured using a Hardness Tester (manufactured by Fujiwara Seisakusho).
The degree of neutralization of component (C) / component (B) in each tablet, the ratio of the total content of component (B) and component (C) to the content of component (A) (content mass ratio), tablet hardness, The thickness and diameter are shown in Table 5.
〔泡安定性の評価〕
試験例49〜55で得た本発明品について泡安定性を同様に評価した。それぞれの理論泡量(mL)、実測量(mL)及び相対泡量(%)を表5に示す。
[Evaluation of foam stability]
The foam stability was similarly evaluated for the products of the present invention obtained in Test Examples 49 to 55. Table 5 shows the theoretical foam volume (mL), the actual measurement volume (mL), and the relative foam volume (%).
〔官能評価〕
試験例49〜55で得た本発明品を食べた時に感じる酸味、苦味とエグ味の強度について、上記と同様に3名の専門パネルによる官能評価を行なった。結果を表5に示す。
〔sensory evaluation〕
With respect to the sourness, bitterness and acridness felt when the products of the present invention obtained in Test Examples 49 to 55 were eaten, sensory evaluation was performed by three expert panels in the same manner as above. The results are shown in Table 5.
表5から明らかなように、本発明品は、相対泡量(%)が高く、胃の中で発泡し、且つ生じた泡が消えることなく長時間安定に持続することが確認された。試験例49と50、試験例51と52、試験例53と54の対比では錠剤の硬度が低いものが泡の持続性が良好であった。また、本発明品は、適度な酸味を有しつつも、苦味とエグ味の少ない良好な風味であった。 As is clear from Table 5, it was confirmed that the product of the present invention has a high relative foam amount (%), foams in the stomach, and the foam generated does not disappear and remains stable for a long time. In contrast to Test Examples 49 and 50, Test Examples 51 and 52, and Test Examples 53 and 54, the one with lower tablet hardness had better foam persistence. In addition, the product of the present invention had a good sourness with little bitterness and astringent taste while having an appropriate sourness.
Claims (5)
(A)HLBが12以上であり、ショ糖脂肪酸エステル及びポリグリセリン脂肪酸エステルから選ばれる1種又は2種以上の可食性界面活性剤 3〜60質量%、
(B)炭酸塩 5〜27質量%、
(C)有機酸 5〜27質量%
を含有し、成分(C)/成分(B)の中和度が1.25〜7であり、且つ成分(A)の含有量に対する成分(B)と成分(C)の合計含有量の比(含有質量比)[{(B)+(C)}/(A)]が0.6〜10である固形状組成物。 The following components (A), (B) and (C):
(A) HLB is 12 or more , and one or more kinds of edible surfactants selected from sucrose fatty acid ester and polyglycerin fatty acid ester 3 to 60% by mass,
(B) Carbonate 5 to 27% by mass,
(C) Organic acid 5 to 27 mass%
And the neutralization degree of component (C) / component (B) is 1.25 to 7, and the ratio of the total content of component (B) and component (C) to the content of component (A). A solid composition in which (content ratio) [{(B) + (C)} / (A)] is 0.6 to 10.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015132776 | 2015-07-01 | ||
| JP2015132776 | 2015-07-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017014211A JP2017014211A (en) | 2017-01-19 |
| JP6682385B2 true JP6682385B2 (en) | 2020-04-15 |
Family
ID=57829074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016130516A Active JP6682385B2 (en) | 2015-07-01 | 2016-06-30 | Solid composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6682385B2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6925211B2 (en) * | 2017-07-10 | 2021-08-25 | 花王株式会社 | Compression molding |
| JP7831988B2 (en) * | 2021-12-24 | 2026-03-17 | 花王株式会社 | Oral foamed solid composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4613497A (en) * | 1984-02-29 | 1986-09-23 | Health Products Development, Inc. | Dry, water-foamable pharmaceutical compositions |
| GR940100370A (en) * | 1993-07-28 | 1994-07-26 | Johnson & Johnson Consumer Products Inc. | A spermicidal anti-viral lubricant composition and method of using same. |
| US6649186B1 (en) * | 1996-09-20 | 2003-11-18 | Ethypharm | Effervescent granules and methods for their preparation |
| CA2770490C (en) * | 2009-08-11 | 2024-04-16 | The Johns Hopkins University | Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products |
-
2016
- 2016-06-30 JP JP2016130516A patent/JP6682385B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017014211A (en) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7141542B2 (en) | Slightly effervescent buccal tablet and its preparation method | |
| KR101203186B1 (en) | Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof | |
| WO1993020718A1 (en) | Food composition which inhibits formation of intestinal putrefaction product | |
| JPWO2006022187A1 (en) | Coenzyme Q10-containing composition | |
| JP2016174616A (en) | Disintegrable composition, and easily disintegrable compression molding | |
| JP5945191B2 (en) | Intraoral quick disintegrating tablet | |
| WO2004078171A1 (en) | Tablet containing water-absorbing amino acid | |
| JP6682385B2 (en) | Solid composition | |
| WO2005004923A1 (en) | Tablet and process for producing the same | |
| JP6092672B2 (en) | Orally rapidly disintegrating tablets | |
| JP5261601B2 (en) | Solid composition | |
| KR20220090615A (en) | Oral disintegrating tablet or sublingual tablet for health functional food | |
| JP6823446B2 (en) | Solid composition | |
| JP6608217B2 (en) | Solid composition | |
| JP6467205B2 (en) | Method for producing foamable solid composition | |
| JP6572055B2 (en) | Solid composition | |
| JP5917078B2 (en) | Solid composition | |
| WO2021038486A1 (en) | Formulations comprising arginine and/or a pharmaceutically acceptable salt thereof and an acid active ingredient with a pka of 1 -5 | |
| JP2010260853A (en) | Granulated powder, granules or tablets containing alanylglutamine | |
| JP5462343B2 (en) | Solid composition | |
| JP6310708B2 (en) | Solid composition | |
| JP7321743B2 (en) | solid composition | |
| JP2015117213A (en) | Solid form composition | |
| JP2018090640A (en) | Solid composition | |
| KR20060135022A (en) | Purification containing branched chain amino acids and method for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190307 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200107 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20191227 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200324 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200325 |
|
| R151 | Written notification of patent or utility model registration |
Ref document number: 6682385 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R151 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |